List of Excipients in Branded Drug DOXEPIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	SILICON DIOXIDE

Generic Drugs Containing DOXEPIN

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	doxepin	0228-3315	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Actavis Pharma Inc	doxepin	0228-3315	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	doxepin	0228-3315	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	doxepin	0228-3315	HYPROMELLOSES

What are the Most Frequently-Used Excipients in DOXEPIN?

# Of NDCs	Excipient
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
12	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
4	CROSPOVIDONE

Excipient Strategy and Commercial Opportunities for Doxepin

Last updated: March 14, 2026

What is the role of excipients in Doxepin formulations?

Excipients stabilize, enhance bioavailability, and improve manufacturability of Doxepin, a tricyclic antidepressant and anxiolytic. Common excipients include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, silica colloidal anhydrous, magnesium stearate, and various binders and disintegrants. These ingredients influence the product's stability, release profile, and patient compliance.

How do excipient choices impact Doxepin’s commercial formulation?

The selection of excipients directly affects manufacturing costs, shelf life, bioavailability, and regulatory approval. For instance, using excipients like lactose can cause issues in lactose-intolerant populations, limiting market reach. Formulation strategies aim to optimize excipient combinations for extended-release (ER) versus immediate-release (IR) forms, broadening therapeutic applications.

What are the strategic considerations for excipient selection in Doxepin products?

1. Safety and tolerability

Choose excipients with established safety profiles, especially for chronic use. Avoid excipients associated with adverse reactions or regulatory restrictions.

2. Compatibility

Ensure excipients are chemically compatible with Doxepin to prevent degradation. Stability studies assess interactions, especially in ER formulations, which require precise control over release kinetics.

3. Regulatory clearance

Use excipients recognized in pharmacopeias (USP, EP, JP). Combining well-documented excipients accelerates approval and reduces time-to-market.

4. Formulation performance

Optimize for desired release profiles. In IR formulations, rapid disintegration is key; in ER, sustained release is critical.

What are commercial opportunities based on excipient strategies?

1. Differentiation through formulation innovation

Develop ER Doxepin formulations using proprietary excipient blends like osmotic systems or matrix tablets, improving adherence and creating patent barriers.

2. Expanding indications

Formulations targeting specific patient groups—such as long-acting versions for depression or sleep disorders—can command premium pricing.

3. Market expansion

By choosing excipients suited for various routes or populations (e.g., pediatric or geriatric-friendly excipients), companies can access new segments.

4. Generic and biosimilar markets

Standardized excipient use facilitates generic versions, increasing market penetration and price competition.

How does excipient patenting influence the commercial landscape?

Patents on excipient combinations or novel excipient matrices can extend product lifecycle. Companies file patents covering excipient use in ER systems or minimizing side effects, creating barriers to generic entry.

What are the regulation considerations for excipients in Doxepin?

The FDA recognizes specific excipients as Generally Recognized As Safe (GRAS). Any new excipient or novel combination requires supporting data on safety, stability, and bioavailability. Labeling must disclose excipients, especially those known allergens like lactose or gluten.

What is the outlook for excipient-driven innovation in Doxepin?

Emerging trends include the integration of functional excipients delivering targeted release or reducing side effects. Nanotechnology-based excipients and bioresorbable polymers hold potential for advanced delivery systems, opening new commercialization pathways.

Key Takeaways

• Excipient choices influence Doxepin's stability, release profile, patient tolerability, and regulatory approval.
• Strategic excipient selection facilitates formulation differentiation, patenting opportunities, and market expansion.
• Innovation in excipient technology supports tailored delivery systems, improving therapeutic outcomes.
• Regulatory compliance with excipient standards streamlines product approval.
• The growing focus on personalized medicine underscores the importance of excipient customization.

FAQs

1. Can excipients impact Doxepin’s bioavailability?
Yes. Excipients influence drug release and absorption, especially in sustained-release formulations, affecting overall bioavailability.

2. Are there concerns with excipients like lactose in Doxepin formulations?
Yes. Patients with lactose intolerance may experience adverse effects, limiting use in certain populations.

3. What patents cover excipients in Doxepin formulations?
Patents often cover novel excipient combinations, delivery systems like osmotic pumps, or specific matrix formulations aimed at extended release.

4. How do regulatory agencies view excipients in Doxepin?
Agencies prefer excipients with established safety profiles. New excipients require thorough safety and stability data.

5. What future trends are shaping excipient development for Doxepin?
Integration of biocompatible polymers, bioresorbable matrices, and nanotechnology aims to improve targeted delivery and reduce side effects.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Safety Evaluation of Excipient in Drug Products.
[2] OECD. (2019). OECD Guidelines for Testing of Chemicals: Dissolution Testing.
[3] USP. (2022). USP Dictionary of USAN and International Drug Names.
[4] Patel, V. et al. (2021). Advances in formulation of TRICYCLIC Antidepressants. Journal of Pharmaceutical Sciences, 110(3), 1234–1245.